For the year ending 2025-12-31, BBOT had $342,836K increase in cash & cash equivalents over the period. -$114,500K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -134,044 |
| Depreciation of property and equipment | 280 |
| Stock-based compensation | 5,873 |
| Fair value of common stock issued to related party | -7,769 |
| Change in fair value of participation right liability | 725 |
| Net accretion of premiums on marketable securities | 1,260 |
| Amortization of right-of-use assets | 330 |
| Prepaid expense and other currents assets | 3,417 |
| Other non-current assets | 7,581 |
| Accounts payble | -1,840 |
| Accrued compensation and benefits | 1,925 |
| Accrued research and development liabilities | 17,675 |
| Accrued professional services | -102 |
| Operating lease liabilities | -47 |
| Other accrued liabilities | 74 |
| Balances due to and from related parties | 254 |
| Net cash used in operating activities | -113,894 |
| Maturities of marketable securities | 157,859 |
| Purchases of marketable securities | 83,925 |
| Change in related party receivables related to cash pooling arrangement | 0 |
| Purchases of property and equipment | 606 |
| Net cash provided by (used in) investing activities | 73,328 |
| Proceeds from reverse recapitalization and pipe financing | 373,457 |
| Payment of deferred transaction costs | 12,322 |
| Issuance of series a redeemable convertible preferred stock | 0 |
| Issuance of series b redeemable convertible preferred stock, net of issuance costs | 22,222 |
| Contribution from bridgebio pharma | 0 |
| Exercise of common stock options for cash | 45 |
| Net cash provided by financing activities | 383,402 |
| Net increase in cash, cash equivalents, and restricted cash | 342,836 |
| Cash, cash equivalents, and restricted cash at beginning of period | 30,983 |
| Cash, cash equivalents, and restricted cash at end of period | 373,819 |
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)